-

Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx management will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference. The presentation will take place on Wednesday, February 12, 2025, at 2:00 p.m. ET.

A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the event.

About Amylyx Pharmaceuticals

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative, neuroendocrine, and endocrine diseases in which we believe they can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.

Contacts

Media
Amylyx Media Team
+1 (857) 799-7274
amylyxmediateam@amylyx.com

Investors
Lindsey Allen
Amylyx Pharmaceuticals, Inc.
+1 (857) 320-6244
Investors@amylyx.com

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Release Summary
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Release Versions
$Cashtags

Contacts

Media
Amylyx Media Team
+1 (857) 799-7274
amylyxmediateam@amylyx.com

Investors
Lindsey Allen
Amylyx Pharmaceuticals, Inc.
+1 (857) 320-6244
Investors@amylyx.com

Social Media Profiles
More News From Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol, in adults living with Wolfram syndrome have been published in The Journal of Clinical Investigation, a peer-reviewed medical journal. The publication reports Week 24 and Week 48 results from the Phase 2 ope...

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results...

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences...
Back to Newsroom